Kalbitor

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
02420102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Dublin-based Shire has agreed to buy Dyax, a company with a rare disease treatment that bolsters its current portfolio in… (More)
Is this relevant?
2016
2016
  • Nature Biotechnology
  • 2016
Dublin-based Shire has agreed to buy Dyax, a company with a rare disease treatment that bolsters its current portfolio in… (More)
Is this relevant?
Review
2013
Review
2013
  • Nature Biotechnology
  • 2013
1 2012 was not a banner year for sales of newly launched biotech drugs. Revenues of Regeneron’s decoy receptor Zaltrap were… (More)
Is this relevant?
Review
2013
Review
2013
Hereditary angioedema (HAE) is a genetic syndrome caused by a functional deficit in complement C1 inhibitor that results in… (More)
Is this relevant?
2010
2010
DOI 10.2146/news100005 Dyax Corp. on December 1 announced that FDA approved the marketing of the company’s ecallantide injection… (More)
Is this relevant?
2010
2010
New antibody approved for chronic lymphocytic leukaemia p101 In 2009, 19 new molecular entities (NMEs) and 6 biologic licence… (More)
  • figure 1
  • table 1
  • table 2
  • table 2
Is this relevant?
Review
2010
Review
2010
Ecallantide (Kalbitor, Dyax Corporation) is a highly specific recombinant plasma kallikrein inhibitor developed for treatment of… (More)
Is this relevant?
2010
2010
H ereditary angioedema (HAE), an autosomal dominant disorder that occurs in approximately 1 in 50,000 people, is characterized by… (More)
Is this relevant?